OSIPR OSI Pharmaceuticals Inc featured news, full reports, and detailed charts
OSI Pharmaceuticals Inc (OSIPR/OSIPR.PK) Wrap Up:
OSI Pharmaceuticals, Inc., a biotechnology company, discovers, develops, and commercializes molecular targeted therapies for oncology, diabetes, and obesity in the United States and internationally. Its flagship product, Tarceva (erlotinib) is a small molecule inhibitor of the epidermal growth factor receptor, which is used for the treatment of advanced non-small cell lung cancer, as well as for the treatment of patients with locally advanced and metastatic pancreatic cancer in combination with the chemotherapy agent, gemcitabine. The company also offers Macugen for the treatment of neovascular age-related macular degeneration; and Novantrone, an anthracenedione used as an intravenous chemot...OSI Pharmaceuticals Inc (OSIPR:OTC)
|
Market Cap
1.9B
|
Total Revenue
402.6M
|
|
|
EBITDA
146.5M
|
DILUTED EPS TTM
6.51
|
|
|
P/E
5.2x
|
P/S
4.7x
|
|
|
Return On Asset
9.28
|
Return On Equity
95.31
|
|
| K = Thousands M = Millions B = Billions | ||
related news
S&P's latest list finds top-ranked stocks that tend to be less volatile than the broader market. Among them: Genentech, PepsiCo, and Wal-Mart
OSIPR Top Compensated Officers
Executives, Board Directors
Key developments for OSI Pharmaceuticals Inc (OSIPR)
OSI Pharmaceuticals Inc. announced that the Oncologic Drugs Advisory Committee (ODAC) will review the use of Tarceva(R) (erlotinib) as a first-line maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following first-line treatment with platinum-based chemotherapy at its December 16, 2009 meeting. The ODAC panel is a committee of external experts, formed by the U.S. Food and Drug Administration (FDA), to advise the FDA in the evaluation of marketed and investigational drugs for use in the treatment of cancer. In June 2009, the FDA accepted for filing and review the supplemental New Drug Application (sNDA) for the use of Tarceva as a first-line maintenance treatment for patients with advanced NSCLC who have not progressed following first-line treatment with platinum-based chemotherapy. In addition, the overall survival data was included in an update to the U.S. sNDA. The FDA Prescription Drug Fee Act (PDUFA) review date for the Tarceva application is on or about January 18, 2010.
To provide an overview on the company's product portfolio and business developments
To provide an overview on the company's product portfolio and business developments
OSIPR Competitors
| Company | Last | Change |
| Abraxis Bioscience Inc | $33.85 USD | +0.37 |
| Celera Group | $6.25 USD | -0.05 |
| ONYX Pharmaceuticals Inc | $27.99 USD | +0.10 |
| Regeneron Pharmaceuticals Inc | $18.46 USD | -0.21 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | OSIPR | Industry Range |
| Price/Earnings | 5.2x |
|
| Price/Sales | 4.7x |
|
| Price/Book | 2.8x |
|
| Price/Cash Flow | 4.5x |
|
| TEV/Sales | 2.5x |
|
|
OSIPR |
||
OSIPR transactions
| Type Date |
Target |
|
Private Placement
July 21, 2009 |
AVEO Pharmaceuticals, Inc. |
